Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 108

Results For "SEC"

2504 News Found

GenWorks introduces mechanical hysteroscopic tissue removal system
News | July 28, 2023

GenWorks introduces mechanical hysteroscopic tissue removal system

Uses a simple mechanical approach for removing intrauterine tissues


InnoCare gets approval of clinical trial of Zurletrectinib for the treatment of pediatric patients in China
News | July 26, 2023

InnoCare gets approval of clinical trial of Zurletrectinib for the treatment of pediatric patients in China

Zurletrectinib was developed to treat advanced or metastatic solid tumors harboring NTRK fusion genes


ABDM supports the integration of digital health infrastructure
Digitisation | July 24, 2023

ABDM supports the integration of digital health infrastructure

Health-tech startups have the potential to revolutionize the healthcare sector by supporting innovations


Need to strengthen food safety scientific standards: NITI Aayog
Policy | July 24, 2023

Need to strengthen food safety scientific standards: NITI Aayog

There is a pressing need for continuous improvement and innovation in food safety systems to keep pace with emerging food trends and habits


13.91 crore teleconsultations have been completed:PIB
Policy | July 24, 2023

13.91 crore teleconsultations have been completed:PIB

1. 10 crore teleconsultations have been rendered to senior citizens and 5,22,15,224 to women


India brings traditional medicine at the forefront of India’s G20 presidency discourse: Amitabh Kant
News | July 24, 2023

India brings traditional medicine at the forefront of India’s G20 presidency discourse: Amitabh Kant

Traditional medicine effectively highlighted in all health and engagement working groups meeting and Ministry of Ayush acknowledges these efforts


Lonza delivers 5.6% CER sales growth and 30% CORE EBITDA margin
News | July 22, 2023

Lonza delivers 5.6% CER sales growth and 30% CORE EBITDA margin

Good momentum in commercial CDMO business


Merck receives positive EU CHMP opinion for pembrolizumab plus Trastuzumab and Chemotherapy as first-line treatment for HER2-positive advanced gastric or gastroesophageal junction
Drug Approval | July 22, 2023

Merck receives positive EU CHMP opinion for pembrolizumab plus Trastuzumab and Chemotherapy as first-line treatment for HER2-positive advanced gastric or gastroesophageal junction

If approved, KEYTRUDA would be the first immunotherapy for the first-line treatment of HER2-positive advanced gastric or GEJ cancer in tumors expressing PD-L1 (CPS ?1) in the EU